Late-Breaking Clinical Trial Presented at the American College of Cardiology Supports Low-Dose Colchicine, 0.5 mg to Treat Cardiovascular Disease by Reducing Progression of Coronary Plaque
AGEPHA Pharma USA, LLC, is pleased to highlight clinical data that provides new information about how low-dose colchicine, 0.5 mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease. The study titled, “Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease Compared To Placebo: The Ekstrom Trial,” was presented as a late-breaking clinical trial at the American College of Cardiology 74th Annual Scientific Session and Expo (ACC.25). These new data reinforce the use of LODOCO® (colchicine, 0.5 mg tablet), the first anti-inflammatory atheroprotective cardiovascular treatment, to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease.
